Join to View Full Profile
10903 New Hampshire AveBuilding 22, Room 2218Silver Spring, MD 20993
Phone+1 301-796-4099
Dr. Theoret is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2005 - 2009
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2002 - 2005
Pennsylvania State University College of MedicineClass of 2001
Certifications & Licensure
MD State Medical License 2005 - 2025
American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase 1 Mutation.Ashley C Woods, Kelly J Norsworthy, Moran Choe, Brenda J Gehrke, Haiyan Chen
Clinical Cancer Research. 2025-01-06 - 1 citationsFDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-Cell Lymphomas.Maryam Sarraf Yazdy, Yvette L Kasamon, Wenjuan Gu, Lisa R Rodriguez, Susan Jin
Clinical Cancer Research. 2024-12-16 - 1 citationsFDA Approval Summary: Teclistamab-A Bispecific CD3 T-Cell Engager for Patients with Relapsed or Refractory Multiple Myeloma.Andrea C Baines, Bindu Kanapuru, Jay Zhao, Lauren S L Price, Nan Zheng
Clinical Cancer Research. 2024-12-16
Authored Content
- How to Get the Dose RightApril 2022
Press Mentions
SITC Announces Co-Sponsored Workshop with U.S. Food and Drug Administration on Immune-Modified Response Criteria in Cancer Immunotherapy Clinical TrialsOctober 12th, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
